We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
- Authors
Fukuoka, Masahiro; Yano, Seiji; Giaccone, Giuseppe; Tamura, Tomohide; Nakagawa, Kazuhiko; Douillard, Jean-Yves; Nishiwaki, Yutaka; Vansteenkiste, Johan; Kudoh, Shinzoh; Rischin, Danny; Eek, Richard; Horai, Takeshi; Noda, Kazumasa; Takata, Ichiro; Smit, Egbert; Averbuch, Steven; Macleod, Angela; Feyereislova, Andrea; Dong, Rui-Ping; Baselga, José
- Abstract
To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with pretreated advanced non-small-cell lung cancer (NSCLC).
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Vol 21, Issue 12, p2237
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2003.10.038